Ibogaine Treatment in Mexico Cost

Ibogaine treatment is increasingly popular in Mexico for addiction recovery. This powerful psychoactive substance is used in specialized clinics to aid in overcoming addiction.

The cost of Ibogaine treatment in Mexico ranges from $4,000 to $20,000, depending on factors such as the clinic’s reputation, level of medical supervision, accommodation quality, included therapies, and whether the center offers basic care or luxury services.

The short version before you read anything else

Ibogaine is an experimental psychedelic used primarily to interrupt opioid withdrawal. It is not approved by the FDA and remains a Schedule I controlled substance in the United States under 21 CFR 1308.11. It is not scheduled in Mexico, which is why clinics operate there — but “not scheduled” is not the same as “regulated and approved.”

The treatment carries a documented risk of sudden cardiac death from QT-interval prolongation and torsades de pointes. A 2012 systematic review of ibogaine-associated fatalities in Journal of Forensic Sciences identified 19 deaths occurring outside West Central Africa between 1990 and 2008, most in non-hospital settings; subsequent case reports and a 2021 updated systematic review of adverse events in Forensic Toxicology have added to that total. Industry reporting in April 2026 referenced more than 30 deaths in the medical literature.

Ibogaine clinics in Mexico typically quote between $4,000 and $20,000. Those numbers are accurate as a range. What they don’t tell you is whether the clinic you’re considering has a licensed cardiologist on site, continuous telemetry, or a plan for the next ICU bed if something goes wrong. That is the question that determines whether the price is fair — not the thread count of the sheets.

This article covers what the evidence shows, what Mexican law actually says, how to identify a clinic that meets minimum cardiac-safety standards, and who should not consider ibogaine under any circumstances.

Important note (April 2026): On April 18, 2026, the White House issued an executive order, “Accelerating Medical Treatments for Serious Mental Illness,” directing the FDA and DEA to facilitate a Right to Try pathway for psychedelic drugs including “ibogaine compounds,” and accelerating domestic clinical research. As of this writing, ibogaine remains a Schedule I controlled substance in the U.S. and is not FDA-approved; the executive order initiates a regulatory process but does not change the drug’s legal status or approve any clinical use. U.S. insurance coverage is not available. If you are weighing travel to Mexico for ibogaine, nothing in the order reduces the cardiac-safety issues discussed below.

What the data shows

Evidence for efficacy

The strongest evidence for ibogaine is in opioid withdrawal interruption — not long-term addiction cure. A 2018 observational study by Brown and Alper in The American Journal of Drug and Alcohol Abuse followed 30 patients treated at a Mexican clinic. Subjective opioid withdrawal scores fell significantly within roughly 76 hours of a single ibogaine dose. Abstinence at follow-up was highest at 1 month (50%) and declined over time — reported at 23% at 12 months by secondary analyses of the data. A parallel New Zealand observational study by Noller, Frampton, and Yazar-Klosinski in the same journal followed 14 participants over 12 months and also reported significant reductions in withdrawal and sustained reductions in drug use for a subset.

Both studies were observational, not randomized, had no placebo control, and enrolled self-selected patients. There is no completed Phase 3 trial. A UK Phase 1/2a trial of ibogaine HCl (DMX-1002) sponsored by DemeRx (now part of AtaiBeckley) received MHRA approval in 2021 and began dosing at a Manchester clinical unit; the program is ongoing as of early 2026 (psychedelic industry directory). In 2025, Texas allocated $50 million to fund ibogaine research toward FDA approval, and the April 2026 federal executive order above has opened a pathway for the first domestic human trials.

For cocaine, methamphetamine, alcohol, and nicotine, evidence is largely anecdotal. Claims that ibogaine “resets brain receptors” are a simplification — the proposed mechanism involves NMDA antagonism, kappa-opioid activity, and a long-acting metabolite called noribogaine — but the clinical significance of these mechanisms in humans remains unsettled in the peer-reviewed literature.

What Mexican clinics charge (as of April 2026)

These ranges reflect publicly reported industry figures, including recent reporting in April 2026 that a Cancun-based clinic charges $15,000–$20,000 per person. Prices change and package inclusions vary. Any number on a blog post ages poorly — request a written quote on letterhead with an expiration date from any clinic you are seriously considering.

Factors that genuinely change the price: whether pre-treatment ECG and liver panel are included, whether a licensed MD is physically present during dosing (versus a “facilitator” only), telemetry during the 12–24 hour peak window, and aftercare/integration. Factors that don’t justify a meaningful price difference: beach views, yoga, and “holistic” packaging.

A note on clinic names

We have removed specific dollar figures attached to specific named clinics. Prices change, packages change, and any number published here can mislead a reader into expecting a price a clinic no longer honors. If you want accurate pricing from a specific clinic, request a written quote on letterhead with an expiration date — not a number from a blog post.

Mexico-specific details: what the regulatory reality is

Legal status

Ibogaine is not a controlled substance under Mexican federal law. Article 245 of Mexico’s Ley General de Salud classifies psychotropic substances into five groups; Fraction I (the most restricted) lists substances such as LSD, mescaline, DMT, psilocybin, and MDMA, but it does not list ibogaine. This is the legal basis Mexican clinics rely on.

What this does not mean:

• It does not mean COFEPRIS (Mexico’s FDA-equivalent, Comisión Federal para la Protección contra Riesgos Sanitarios) has approved ibogaine for any indication. It has not.
• It does not mean ibogaine clinics are licensed as hospitals. Most operate as private residential facilities or are registered under business categories that do not require hospital-grade licensing.
• It does not mean medical professionals administering ibogaine are specifically credentialed in its use. There is no Mexican specialty board for psychedelic medicine.

Clinic licensing — what to actually ask for

A legitimate clinic should be able to produce, in writing:

1. A COFEPRIS registration number (aviso de funcionamiento) for the facility.
2. The Mexican medical license (cédula profesional) of the supervising physician, issued by the Dirección General de Profesiones of the Secretaría de Educación Pública. Every licensed physician in Mexico has a cédula number that can be checked at the SEP’s public Registro Nacional de Profesionistas.
3. Accreditation by a recognized body. In Mexico, the Consejo de Salubridad General (CSG) accredits hospitals for safety standards; internationally, Joint Commission International (JCI) is the most recognized hospital accreditation. JCI accreditation is rare among ibogaine-specific clinics — do not assume it.

Doctor training

There is no residency or fellowship in ibogaine medicine. Physicians working at these clinics are typically general practitioners, internists, or (less often) emergency medicine or cardiology specialists. The relevant question is not “is the doctor qualified?” but “is the doctor qualified to manage a cardiac arrest at 2 a.m. in this specific facility?”

Visa and documentation

U.S. citizens entering Mexico receive a Forma Migratoria Múltiple (FMM) tourist permit. The maximum stay is 180 days, but the number of days is at the discretion of the immigration officer at the port of entry; recent reporting indicates officers are increasingly granting shorter stays (30 days or fewer), particularly without proof of return ticket or funds. Confirm the number written on your form before leaving the counter. No medical visa is required. Patients should bring:

• Photo ID and passport valid at least 6 months past entry
• Complete medical records (cardiac history especially), including any recent ECG
• Current medication list
• Emergency contact information for someone in the U.S.

Safety and the security environment in Mexico

The U.S. State Department currently maintains a Level 2 “Exercise Increased Caution” advisory for Mexico, with state-by-state variations. Of the regions hosting ibogaine clinics: Quintana Roo (Cancun, Playa del Carmen, Tulum) is at Level 2, while Baja California (Tijuana, Rosarito) is at Level 3 – Reconsider Travel due to organized-crime violence. Security conditions changed materially in February 2026, with shelter-in-place alerts issued for multiple Mexican states including Baja California and Jalisco. Check the current advisory and any U.S. Embassy alerts before booking travel.

Language support — what’s actually true

In clinics serving U.S. and Canadian patients, English-speaking staff is standard, but “staff” often means facilitators and intake coordinators — not necessarily the attending physician. Ask specifically whether the physician supervising your dosing speaks fluent English, and whether medical records (ECGs, lab results, discharge notes) are provided in English.

Risks and red flags

The cardiac problem

Ibogaine and its active metabolite noribogaine block the hERG potassium channel, which prolongs the QT interval on an ECG. Work by Koenig and colleagues in Addiction Biology first demonstrated this mechanism in human cells, and a later study by Rubi, Koenig and colleagues in Cardiovascular Toxicology provided the first experimental proof that therapeutic concentrations of ibogaine and noribogaine retard cardiac repolarization in human ventricular-like cardiomyocytes. Prolonged QT can trigger torsades de pointes, a polymorphic ventricular tachycardia that can cause sudden death. Published case reports — including QT prolongation and torsades de pointes in a 39-year-old man and ibogaine-associated ventricular tachyarrhythmias in a 33-year-old man — document that the effect can occur hours to days after dosing, not just during peak effect. Because noribogaine persists longer than the parent drug, QTc prolongation can remain measurable up to 12 days after ingestion in some cases.

Documented ibogaine-related deaths share a pattern: the patient had a pre-existing medical comorbidity (often cardiovascular, sometimes unknown to them), and/or had recently used other substances, and was dosed in a setting without continuous ECG monitoring. Many collapsed during the night when observation was minimal.

Who should not travel for ibogaine

• Anyone with a personal or family history of long QT syndrome, arrhythmia, or sudden cardiac death
• Anyone with active coronary artery disease, heart failure, or cardiomyopathy
• Anyone with significant liver disease (ibogaine is hepatically metabolized, primarily by CYP2D6, and poor metabolizers are at elevated risk)
• Anyone on medications that prolong QT (certain antidepressants, antipsychotics, methadone, some antibiotics — the list is long and overlaps heavily with the medications addiction patients are often on)
• Anyone actively using stimulants in the days prior
• Pregnant patients
• Anyone who cannot complete a pre-treatment cardiac workup including ECG, electrolytes (especially magnesium and potassium), and ideally an echocardiogram

Warning signs of a clinic to avoid

• Will not provide the supervising physician’s cédula number in writing before you travel
• Does not require a pre-treatment ECG and comprehensive metabolic panel
• Does not use continuous cardiac telemetry during and after dosing (a pulse oximeter is not telemetry)
• “Facilitator” rather than a licensed physician supervising dosing
• No written protocol for transfer to a hospital with cardiac capability, and no named hospital within a defined distance
• Cash-only or cryptocurrency-only payment
• No written informed consent document listing cardiac risk and fatality rate
• Pressure to commit quickly, discount for immediate booking
• Refuses to let you speak with past patients who consented to contact
• Claims ibogaine “cures” addiction, or cites success rates above what published literature supports

Regulatory context

• DEA / eCFR — Schedule I listing of ibogaine (21 CFR 1308.11)
• White House Executive Order on Accelerating Medical Treatments for Serious Mental Illness (April 18, 2026) — addresses ibogaine research and Right to Try access; does not change Schedule I status or approve clinical use
• COFEPRIS (Mexico’s health regulator) — no public ibogaine-specific approval or warning at time of writing
• U.S. State Department Mexico Travel Advisory

Questions to ask before you book

Write these down. Send them by email. Keep the written responses.

1. What is the cédula profesional number of the physician supervising my dose? (You can verify it at cedulaprofesional.sep.gob.mx before you travel.)
2. Will that same physician be physically present in the building during the 24 hours following my dose, or is coverage handed off?
3. What is the name and address of the hospital you transfer to in a cardiac emergency, and what is the transit time by ambulance at 2 a.m.?
4. What pre-treatment cardiac workup is required, and will you refuse to dose me if my QTc is above 450 ms?
5. Is continuous ECG telemetry used during and after dosing, and for how many hours? Who reads it in real time?
6. What is your facility’s documented complication rate, and how many patients have required hospital transfer in the past 24 months?
7. Is your facility registered with COFEPRIS, and what is the aviso de funcionamiento number?
8. What is your written informed consent document, and can I review it in English before I pay a deposit?
9. What is your refund policy if I am medically disqualified during pre-screening after I arrive?
10. What is the name and dose of any pre-treatment medication (including magnesium loading) you use, and who prescribes it?
11. Who is the named point of contact for medical questions after I return home, and for how long?
12. What malpractice insurance does the supervising physician carry, and is the policy enforceable by a U.S. patient?
13. Can I speak with two past patients from the last 12 months who have consented to contact?
14. Do you provide discharge paperwork — including ECG strips, medication record, and a discharge summary — in English for my U.S. physician?

What UMT provides — and what it doesn’t

Universal Medical Travel is a medical travel facilitator. We help patients gather information, request quotes from clinics, and coordinate logistics. We are not a medical provider. We do not administer ibogaine, we do not employ physicians, and we do not verify individual clinical decisions.

What we do check: whether a clinic provides a COFEPRIS aviso de funcionamiento number and whether the supervising physician’s cédula is verifiable in the SEP registry. What we do not and cannot check: whether a specific clinic is the right fit for your specific cardiac risk profile, what the outcome of your treatment will be, or whether ibogaine is appropriate for you at all. Those determinations require a physician who has reviewed your complete medical history — ideally a cardiologist and an addiction medicine specialist, independently — before you decide to travel.

For ibogaine specifically, UMT recommends that every patient obtain an independent pre-travel cardiac evaluation in their home country and bring the records with them.

If you or someone you love is in crisis: In the United States, SAMHSA’s National Helpline is a free, confidential, 24/7 treatment referral service at 1-800-662-4357. If you are having thoughts of suicide or self-harm, call or text 988. If this article is being read because a loved one is in acute withdrawal or relapse right now, calling one of those numbers before booking overseas travel is the right first step.

FAQ

Is ibogaine legal in Mexico?
Ibogaine is not listed as a controlled substance under Article 245 of Mexico’s Ley General de Salud, so clinics can legally administer it. This is not the same as COFEPRIS approval, which does not exist for ibogaine.

Is ibogaine FDA-approved in the United States?
No. Ibogaine is a Schedule I controlled substance in the U.S. and has no FDA-approved indication. A White House executive order issued April 18, 2026 directs regulators to accelerate ibogaine research and establish a Right to Try pathway, but this does not approve ibogaine for clinical use; FDA approval requires completed clinical trials demonstrating safety and efficacy.

How dangerous is ibogaine, really?
The primary serious risk is cardiac — QT prolongation leading to potentially fatal arrhythmia. The 2012 Alper et al. review in Journal of Forensic Sciences documented 19 ibogaine-associated deaths outside West Central Africa between 1990 and 2008, most in non-hospital settings; additional case reports and a 2021 adverse-events review have expanded the record, and news reporting in 2026 cited over 30 deaths linked in medical literature. Most documented deaths involved pre-existing cardiac risk or co-ingested substances. The risk can be reduced — but not eliminated — by proper pre-screening and continuous telemetry.

Does ibogaine actually work for opioid addiction?
Observational studies show it can sharply reduce acute opioid withdrawal symptoms. In Brown and Alper’s 30-patient cohort, half reported no opioid use at 1 month; abstinence rates declined over 12 months. There is no randomized controlled trial demonstrating superiority to standard medication-assisted treatment. For most patients with opioid use disorder, FDA-approved MAT — methadone, buprenorphine, or extended-release naltrexone — is the evidence-based first line.

Is ibogaine the same as ayahuasca?
No. They are different plants with different active compounds and different pharmacology. Ibogaine’s cardiac risk profile is distinct and more severe than ayahuasca’s.

What about ibogaine for alcohol, cocaine, or nicotine?
Evidence is largely anecdotal. There is no strong clinical data supporting ibogaine for these indications, and the cardiac risk is the same.

Can I use my U.S. health insurance?
No. U.S. insurers do not cover ibogaine treatment because it is not FDA-approved. Treatment is out-of-pocket. Industry representatives confirmed in April 2026 reporting that the recent executive order does not change coverage status.

What happens if something goes wrong and I’m in Mexico?
That depends entirely on the clinic’s emergency protocol and the quality of the nearest hospital. Ask for the written protocol and named transfer hospital before you book. Consider travel medical insurance that explicitly covers experimental treatment and medical evacuation.

Sources Cited

1. eCFR (Electronic Code of Federal Regulations), 21 CFR 1308.11 Schedule I. Current through March 2026. https://www.ecfr.gov/current/title-21/chapter-II/part-1308/subject-group-ECFRf62f8e189108c4d/section-1308.11
2. Alper KR, Stajić M, Gill JR. Fatalities temporally associated with the ingestion of ibogaine. J Forensic Sci. 2012;57(2):398–412. https://pubmed.ncbi.nlm.nih.gov/22268458/
3. Ona G, Rocha JM, Bouso JC, et al. The adverse events of ibogaine in humans: an updated systematic review (2015–2020). Forensic Toxicol. 2021. https://pubmed.ncbi.nlm.nih.gov/34406452/
4. Brown TK, Alper K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. Am J Drug Alcohol Abuse. 2018;44(1):24–36. https://pubmed.ncbi.nlm.nih.gov/28541119/
5. Noller GE, Frampton CM, Yazar-Klosinski B. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. 2018;44(1):37–46. https://pubmed.ncbi.nlm.nih.gov/28402682/
6. Koenig X, Kovar M, Boehm S, Sandtner W, Hilber K. Anti-addiction drug ibogaine inhibits hERG channels: a cardiac arrhythmia risk. Addict Biol. 2014;19(2):237–239. https://pubmed.ncbi.nlm.nih.gov/22458604/
7. Koenig X, Hilber K. The anti-addiction drug ibogaine and the heart: a delicate relation. Molecules. 2015;20(2):2208–2228. https://pubmed.ncbi.nlm.nih.gov/25642835/
8. Rubi L, Eckert D, Boehm S, Hilber K, Koenig X. Anti-addiction drug ibogaine prolongs the action potential in human induced pluripotent stem cell-derived cardiomyocytes. Cardiovasc Toxicol. 2017;17(2):215–218. https://pubmed.ncbi.nlm.nih.gov/27020671/
9. Hildyard C, Macklin P, Prendergast B, Bashir Y. A case of QT prolongation and torsades de pointes caused by ibogaine toxicity. J Emerg Med. 2016;50(1):83–87. https://pubmed.ncbi.nlm.nih.gov/26329675/
10. Pleskovic A, Gorjup V, Brvar M, Kozelj G. Ibogaine-associated ventricular tachyarrhythmias. Clin Toxicol (Phila). 2012;50(2):157. https://pubmed.ncbi.nlm.nih.gov/22304378/
11. Ley General de Salud, Artículo 245 (official legislative text), Cámara de Diputados, Congreso de la Unión (last reforms published DOF 15-01-2026). https://leyes-mx.com/ley_general_de_salud/245.htm
12. The White House. “Accelerating Medical Treatments for Serious Mental Illness” — Executive Order, April 18, 2026. https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/
13. U.S. Department of State. Mexico Travel Advisory. https://travel.state.gov/content/travel/en/traveladvisories/traveladvisories/mexico-travel-advisory.html
14. U.S. Embassy Mexico. Security Alert — Ongoing Security Operations (February 23, 2026). https://mx.usembassy.gov/security-alert-update-4-ongoing-security-operations-u-s-mission-mexico-february-23-2026/
15. COFEPRIS — Comisión Federal para la Protección contra Riesgos Sanitarios. https://www.gob.mx/cofepris
16. Joint Commission International (JCI). https://www.jointcommissioninternational.org/
17. Secretaría de Educación Pública (SEP) — Registro Nacional de Profesionistas / Cédula Profesional. https://www.cedulaprofesional.sep.gob.mx/
18. Instituto Nacional de Migración (INM). Forma Migratoria Múltiple (FMM). https://www.inm.gob.mx/fmme/publico/en/solicitud.html
19. Psychedelic Alpha. Psychedelic Companies Directory (DemeRx / AtaiBeckley DMX-1002). https://psychedelicalpha.com/news/demerx-receives-mhra-approval-for-dmx-1002-ibogaine-to-commence-phase-1-2a-study-as-first-clinical-trial-in-opioid-use-disorder-in-the-uk
20. Associated Press / CNBC (April 18, 2026). “Trump signs order to speed review of psychedelics, including the controversial drug ibogaine.” https://www.cnbc.com/2026/04/18/trump-executive-order-psychedelic-drugs-ibogaine.html

Important: This article provides general information about ibogaine and medical travel to Mexico and is not medical advice. Ibogaine carries specific and documented risks, including potentially fatal cardiac arrhythmia (QT prolongation and torsades de pointes), and is not appropriate for all patients. Ibogaine is an experimental treatment that is not approved by the FDA in the United States and is not approved by COFEPRIS in Mexico; it is administered in Mexico only because it is not specifically scheduled as a controlled substance under Mexican federal law. Verify regulatory status and current legal standing before proceeding. Outcomes vary by individual, and international medical travel adds additional risks. Consult a licensed physician — ideally both an addiction medicine specialist and a cardiologist — who has reviewed your complete medical history before making any treatment decision or traveling abroad. Prices, clinic offerings, and regulations change frequently — verify all specifics directly with clinics before committing. Universal Medical Travel is a medical travel facilitator and does not provide medical services.

References

Medical and regulatory sources used to support the information in this article.